Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates
(GRANULES)
XNSE:GRANULES, XBOM:GRANULES
Granules India Ltd Q1FY24; 62% fall in Profits
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates
Granules India Ltd (GRANULES) Q4 FY23 Earnings Concall Transcript
Granules India Ltd (NSE:GRANULES) Q4 FY23 Earnings Concall dated May. 16, 2023. Corporate Participants: Irfan Raeen -- Investor Relations Krishna Prasad -- Chairman and Managing Director
Granules India Limited Q4 FY23; Net Profit Increased By 8%
Granules India Limited reported Total Income for Q4 FY23 of ₹1,198.87 Crore up from ₹1,033.93 Crore year on year, a growth of
Earnings Summary Of Granules India Limited For Q4 FY23
Granules India Limited is a pharmaceutical manufacturing company based in India. The company is engaged in the production and sale of active
Earnings Summary Of Granules India Limited For Q3 FY23
Granules India Limited (NSE: GRANULES) is a pharmaceutical manufacturing company based in Hyderabad, India. The company was founded in 1984 and has
Granules India Limited Q3 FY23; PAT Jumped Up To 124 Crore
Granules India Limited (NSE: GRANULES) reported Revenue from Operations for Q3 FY23 of ₹1,146.12 Crore up from ₹996.76 Crore year on year,
Granules India Ltd (GRANULES) Q3 FY23 Earnings Concall Transcript
Granules India Ltd (NSE: GRANULES) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Irfan Raeen -- Investor Relation Advisor Krishna Prasad Chigurupati -- Chairman
Granules India Ltd (GRANULES) Q2 FY23 Earnings Concall Transcript
Granules India Ltd (NSE:GRANULES) Q2 FY23 Earnings Concall dated Oct. 20, 2022 Corporate participants: Irfan Raeen -- Investor Relation Dr. Krishna Prasad